Belgium

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190

OptimUM-10 – Darovasertib before treatment for primary uveal melanoma Phase: Phase 3Trial ID: NCT07015190Treatment: DarovasertibStage: Primary uveal melanoma – the cancer must not have spread to other parts of the bodyUK locations: University College London Hospital and The Clatterbridge Cancer Centre, Liverpool What is this trial looking at? OptimUM-10 is investigating whether giving a drug called darovasertib before the usual treatment […]

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190 Read More »

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) – NCT06246149

This Phase 3 clinical trial, known as the ATOM study, is investigating whether a drug called tebentafusp can help prevent or delay the return of uveal melanoma in patients who are considered at high risk of their cancer spreading after treatment of the primary tumour. Tebentafusp is an immunotherapy drug that has already shown benefits

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) – NCT06246149 Read More »

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors – NCT07070232 Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) – NCT06007690 Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332 Read More »